Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia
- 1 March 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (3), 626-637
- https://doi.org/10.1158/2159-8290.cd-20-1579
Abstract
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with cytogenetic and molecular factors and patient demographics (e.g., age and race). We compared survival of 25,523 Non-Hispanic Black and White adults with AML using Surveillance Epidemiology and End Results (SEER) Program data, and performed mutational profiling of 1,339 AML patients treated on frontline Alliance for Clinical Trials in Oncology (Alliance) protocols. Black patients had shorter survival than White patients, both in SEER and in the setting of Alliance clinical trials. The disparity was especially pronounced in Black patients <60 years, after adjustment for socioeconomic (SEER) and molecular (Alliance) factors. Black race was an independent prognosticator of poor survival. Gene mutation profiles showed fewer NPM1 and more IDH2 mutations in younger Black patients. Overall survival of younger Black patients was adversely affected by IDH2 mutations and FLT3-ITD, but, in contrast to White patients, was not improved by NPM1 mutations.Other Versions
Funding Information
- NCI
- NIH (U10CA180821, U10CA180882, U24CA196171, UG1CA283338, UG1CA189824, UG1CA233338, U10CA140158, UG1CA233331, U10CA180867, R35CA197734, UG1CA189850, 5P30CA016058)
- Coleman Leukemia Research Foundation
- ASH Junior Faculty Scholar Award
- National Comprehensive Cancer Network Foundation Young Investigator Award
- Alliance for Clinical Trials in Oncology Scholar Award
- D Warren Brown Foundation
This publication has 37 references indexed in Scilit:
- Understanding disparities in leukemia: a national studyCancer Causes & Control, 2012
- RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression SignaturesJournal of Clinical Oncology, 2012
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcomeBlood, 2012
- Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid LeukemiaHematology/Oncology Clinics of North America, 2011
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryBlood, 2011
- FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBlood, 2010
- Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2008
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood, 2006
- Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaBlood, 2004
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002